Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.,Antiviral Therapy

当前位置： X-MOL 学术 › Antivir. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.
Antiviral Therapy ( IF 1.3 ) Pub Date : 2017-6-9 , DOI: 10.3851/imp3177
Fiona McPhee ₁ , Dennis Hernandez ₁ , Nannan Zhou ₁ , Joseph Ueland ₁ , Fei Yu ₁ , Vincent Vellucci ₁ , Xin Huang ₂ , Xuning Wang ₂ , Hiroki Ishikawa ₃ , Yoshiyasu Karino ₄ , Hiromitsu Kumada ₅

Affiliation

Daclatasvir (DCV; non-structural [NS]5A inhibitor) plus asunaprevir (ASV; NS3 inhibitor) plus beclabuvir (BCV; non-nucleoside NS5B inhibitor) is an approved regimen for hepatitis C virus (HCV) genotype (GT)-1 treatment in Japan. A comprehensive analysis of pre-treatment and treatment-emergent HCV resistance to this regimen ± ribavirin (RBV) was performed.

中文翻译：

对 12 周达卡他韦、阿舒瑞韦和贝拉布韦治疗前后 NS5A、NS3 和 NS5B 中 HCV 基因型 1 耐药性相关替代的汇总分析。

达卡他韦（DCV；非结构性 [NS]5A 抑制剂）加阿舒瑞韦（ASV；NS3 抑制剂）加贝拉布韦（BCV；非核苷 NS5B 抑制剂）是丙型肝炎病毒 (HCV) 基因型 (GT)-1 治疗的批准方案在日本。对该方案±利巴韦林 (RBV) 的治疗前和治疗出现的 HCV 耐药性进行了综合分析。

更新日期：2020-08-21

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11